Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant RSV Vaccine (CHO Cell) in Adults Aged ≥60 Years
NCT07860216Phase 3Recruiting
- Sponsor
- Beijing BeneWill Technology Development
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus infection (RSV), sponsored by Beijing BeneWill Technology Development. Started Aug 2026; status: recruiting.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07860216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07860216.